Spyre Therapeutics (SYRE) Q2 2026 earnings summary

Executive summary

• Advanced clinical-stage pipeline focused on next-generation antibody therapies for IBD and rheumatic diseases, with multiple Phase 2 trials underway and key topline data readouts achieved for SPY001 and SPY002 in ulcerative colitis, both meeting primary endpoints and showing favorable safety profiles.

• Positive topline induction data for SPY001 and SPY002 from Part A of the Phase 2 SKYLINE trial, showing best-in-class efficacy and safety consistent with comparators.

• Enrollment completed ahead of schedule for all three sub-studies in the Phase 2 SKYWAY basket trial, reflecting strong investigator interest.

• Expanded development programs into additional indications, including rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis, with the SKYWAY Phase 2 basket trial fully enrolled and data readouts expected in late 2026.

• Six proof-of-concept Phase 2 readouts expected in 2026, including key data for RA, PsA, and axSpA.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $1.15 billion as of June 30, 2026, up from $756 million at year-end 2025, driven by $435.2 million in net proceeds from an April 2026 public offering.

• Net loss for Q2 2026 was $36.2 million, compared to $36.7 million in Q2 2025; net loss for the six months ended June 30, 2026 was $105.2 million, up from $81.5 million in the prior year period.

• Research and development expenses increased to $65.5 million in Q2 2026 from $40.1 million in Q2 2025, reflecting higher clinical and manufacturing costs.

• General and administrative expenses rose to $16.1 million in Q2 2026 from $11.8 million in Q2 2025, primarily due to increased headcount.

• Recognized $40.0 million gain in Q2 2026 and $70.0 million YTD from milestone payments related to the sale of pegzilarginase and a priority review voucher.

Outlook and guidance

• Sufficient liquidity to fund operations for at least one year, with cash runway expected to last into the second half of 2029; additional financing will be needed for long-term development and commercialization.

• Multiple Phase 2 data readouts expected in late 2026 and 2027, including for SPY003 and the SKYWAY basket trial in rheumatic diseases.

• Plans to initiate pivotal development of SPY072 in RA in 2027 if upcoming data are positive.